CXCR4 as a prognostic marker in Egyptian chronic lymphocytic leukemia patients
Egyptian journal of Immunology · 2021
DOI: 10.55133/eji.280312 ↗Kurz gefasst
Fachartikel in der Zeitschrift Egyptian journal of Immunology, 2021. Verfasst von Wafaa El-sherif und 4 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref).
Abstract (Originalsprache)
Chronic lymphocytic leukemia (CLL) has variable clinical presentations, and molecular and biological prognostic markers. The C-X-C chemokine receptor 4 (CXCR4) and its ligand stromal cell-derived factor-1 (SDF-1) play an important role in trafficking of lymphocytes and monocytes. The aim was to study lymphocyte expression of CXCR4 and its prognostic value in CLL. A case control study was carried out on 30 newly diagnosed CLL cases and 30 healthy controls. Fludarabine, cyclophosphamide, and rituximab (FCR) was the standard treatment. Flowcytometric measurement of CXCR4 expression on lymphocytes was done. CXCR4 was significantly higher in patients than controls (81.67 ± 17.95 vs. 11.78 ± 2.78; P< 0.001). CXCR4 was significantly higher (P
Zitieren
APA
El-sherif, W., El-din, E. S., Aly, M., Said, M., & Nigm, D. (2021). CXCR4 as a prognostic marker in Egyptian chronic lymphocytic leukemia patients. Egyptian journal of Immunology. https://doi.org/10.55133/eji.280312
Vancouver
El-sherif W, El-din ES, Aly M, Said M, Nigm D. CXCR4 as a prognostic marker in Egyptian chronic lymphocytic leukemia patients. Egyptian journal of Immunology. 2021. doi:10.55133/eji.280312
BibTeX
@article{Elsherif2021,
author = {El-sherif, Wafaa and El-din, Eman Salah and Aly, Mai and Said, Mohamed and Nigm, Dalia},
title = {CXCR4 as a prognostic marker in Egyptian chronic lymphocytic leukemia patients},
journal = {Egyptian journal of Immunology},
year = {2021},
doi = {10.55133/eji.280312}
}
EUVIMED